Audeo Oncology, which utilizes Hyaluronic Acid Chemotransport Technology to increase the effectiveness of anti-cancer drugs, filed on Friday with the SEC to raise up to $60 million in an initial public offering. Audeo Oncology is a spin-off from Australia's Alchemia Ltd.
The San Francisco, CA-based company, which was founded in 2006 and currently does not generate any revenue from its product candidates, plans to list on the NASDAQ under the symbol AURX. Leerink Swann and Oppenheimer & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
